CEO leaves his position
(Oslo, Norway, 26 April 2016) Bionor Pharma ASA (OSE:BIONOR) today announced that Dr. David Horn Solomon and Bionor’s Board of Directors have agreed that Dr. David Horn Solomon will leave his position as Chief Executive Officer of Bionor Pharma ASA, owing to a shareholder led change in company strategy.
The Board of Directors will immediately initiate a search process for a new CEO. Until such search is concluded, the Board has appointed MSc Pharmacist Unni Hjelmaas as acting CEO. The Board thanks Dr. Solomon for all his service for Bionor Pharma ASA during his tenure for the company.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Per S. Thoresen, Chairman of the Board of Directors, +47 906 14 620
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.